TGFBR1 and neoplasm: Immunohistochemistry analysis of metastatic nodules demonstrated marked mitigation of the FAP+, α‐SMA+, DESMIN+, PDGFRα+, and PDGFRβ+ fibrotic components in TGF‐βR1‐treated Bmal1−/− tumor‐bearing mice (Figure 7C,D).